Mounjaro vs Ozempic: Weight Loss, Diabetes and Costs
Mounjaro and Ozempic are different diabetes medicines.
Tirzepatide produced greater average weight loss in specific trials, but the widely quoted 20.2% versus 13.7% result studied weight-management doses in adults without diabetes. Here is how that changes the comparison.
By GLP-1 Picks, an independent comparison publication. Sources linked below. Our editorial policy.
Summarize this article with

In this article
- 01What Are Mounjaro and Ozempic?
- 02How Do Mounjaro and Ozempic Work?
- 03Which Produces More Weight Loss: Mounjaro or Ozempic?
- 04What Did the Diabetes Trial Actually Compare?
- 05How Do Their Heart and Kidney Indications Compare?
- 06Are Mounjaro and Ozempic Approved for Weight Loss?
- 07What Do Mounjaro and Ozempic Cost?
- 08How Do Their Side Effects Compare?
- 09Frequently Asked Questions
- 10What Is the Next Useful Step?
- 11Sources
Mounjaro and Ozempic can both affect weight, but neither brand is FDA-approved for weight management.
Mounjaro contains tirzepatide; Ozempic contains semaglutide. SURPASS-2 directly compared the molecules in adults with type 2 diabetes, using semaglutide 1 mg rather than Ozempic’s 2 mg maximum.
The often-quoted 20.2% versus 13.7% weight-loss result comes from SURMOUNT-5, a different trial of weight-management doses in adults without diabetes.
If your main goal is weight loss, discuss the relevant approved brands, Zepbound and Wegovy. Heart and kidney conditions, tolerability and coverage can change the decision.
The decision matrix, find your situation:
- •Type 2 diabetes and weight concerns: Ask about the SURPASS-2 results and their limits. Compare the prescribed product and the dose studied before comparing programs.
- •Type 2 diabetes with heart or kidney disease: Both brands now have defined cardiovascular indications; Ozempic also has a kidney-related indication. Mounjaro’s label changed in August 2026. Ask which evidence fits your diagnosis.
- •Weight management without diabetes: Compare the relevant Zepbound and Wegovy indications, rather than assuming an Ozempic or Mounjaro result transfers unchanged.
- •If insurance denies you and you're paying cash → compare Gala’s annual compounded tirzepatide plan from $99/mo, billed yearly, Embody from $79/mo on a selected plan, and every cash path on /cheapest. TrimRx lists GLP-1 at $174 month-to-month or $149/mo on a 12-month plan, and GLP-1 + GIP at $279 month-to-month or $249/mo on 12 months. Confirm the complete payment and renewal; its generic package terms are not confirmed future charges for these price-lock plans.
- •Prefer tablets: Use the oral GLP-1 guide to tell approved oral products apart from compounded dissolving tablets. A compounded tablet is not an approved oral form of Mounjaro.
- •Not sure which fits? Take the 2-minute match quiz or estimate your real out-of-pocket on the cost calculator.
This guide separates glucose-control evidence, weight-management trials and the current Mounjaro and Ozempic labels.
For the broader ingredient and formulation comparison, read semaglutide vs tirzepatide.
See what each one costs and how to get it
Each page lists who prescribes it and what you pay. Your prescriber decides which one suits you.
Explore Mounjaro access and costs →What Are Mounjaro and Ozempic?
Mounjaro is Eli Lilly’s tirzepatide brand.
Its current label covers glucose control in adults and children aged 10 years and older with type 2 diabetes, plus cardiovascular risk reduction in adults with type 2 diabetes at high cardiovascular risk.
It is a weekly injection, with an adult maximum of 15 mg. A clinician determines the dose.
Ozempic is Novo Nordisk’s semaglutide brand.
Its current label covers glucose control in adults with type 2 diabetes, cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease, and specified kidney-related risks in adults with type 2 diabetes and chronic kidney disease.
It is a weekly injection, with a maximum dose of 2 mg.
Neither Mounjaro nor Ozempic is FDA-approved for weight loss. Both are diabetes drugs.
The exact same molecules are sold under different brand names for chronic weight management, tirzepatide as Zepbound, and semaglutide as Wegovy, at different doses with their own clinical trials.
When media coverage says 'Ozempic for weight loss,' they're describing off-label use. We explain why this distinction changes your insurance coverage and your legal options below.
Mounjaro and Zepbound contain tirzepatide; Ozempic and Wegovy contain semaglutide. Shared ingredients do not erase differences in indication, dosing, formulation or trial population.
Use the study that matches the question you are trying to answer.
How Do Mounjaro and Ozempic Work?
The receptor targets differ, but clinical trials, rather than the number of receptors alone, tell us about treatment outcomes.
Ozempic (semaglutide) is a single-agonist, it mimics one gut hormone, GLP-1 (glucagon-like peptide-1).
GLP-1 lowers blood sugar by stimulating insulin release when glucose is high, slows how fast your stomach empties, and acts on appetite centers in the brain to reduce hunger.
Mounjaro (tirzepatide) is a dual agonist, it mimics GLP-1 and a second gut hormone, GIP (glucose-dependent insulinotropic polypeptide), in a single molecule.
The theory, supported by the trial data, is that engaging both incretin pathways improves glucose handling and appetite suppression more than GLP-1 alone. Tirzepatide is the first dual GIP/GLP-1 receptor agonist the FDA approved.
No. The head-to-head trials support advantages for specific measured outcomes at the studied doses. That does not establish one medicine as better for every patient, medical condition or side-effect profile.
Which Produces More Weight Loss: Mounjaro or Ozempic?
The answer depends on the patient group and doses. SURMOUNT-5, published in 2025, is the direct obesity comparison commonly quoted online.
It is not a trial of the maximum approved Ozempic dose in people with diabetes.
SURMOUNT-5 randomized 751 adults with obesity but without type 2 diabetes to the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg) for 72 weeks.
The result: tirzepatide produced −20.2% mean body-weight reduction versus −13.7% for semaglutide, a 6.5 percentage-point advantage that was statistically significant (p<0.001).
In absolute terms, that was roughly 22.8 kg of weight lost on tirzepatide versus 15.0 kg on semaglutide.
Participants on tirzepatide were also more likely to hit the bigger milestones, losing at least 10%, 15%, 20%, and 25% of their body weight, and saw a larger reduction in waist circumference (−18.4 cm vs −13.0 cm).
SURMOUNT-5 studied weight-management injections: tirzepatide 10 or 15 mg and semaglutide 1.7 or 2.4 mg. It did not study Ozempic 2 mg, the newer Wegovy 7.2 mg injection, oral tablets or compounded formulations.
The average result does not predict your outcome. See semaglutide before-and-after evidence for timing and expectations.
What Did the Diabetes Trial Actually Compare?
SURPASS-2, published in 2021, randomized 1,879 adults with type 2 diabetes to tirzepatide 5, 10 or 15 mg or semaglutide 1 mg for 40 weeks.
It is the more relevant head-to-head for the diabetes question.
The published primary analysis reported average HbA1c reductions of 2.01, 2.24 and 2.30 percentage points with tirzepatide 5, 10 and 15 mg, respectively, versus 1.86 percentage points with semaglutide 1 mg.
These are changes in HbA1c, not percentages of body weight lost.
SURPASS-2 did not test semaglutide 2 mg. It cannot tell us the exact difference between the maximum doses of Mounjaro and Ozempic, so we do not estimate that gap from this trial alone.
How Do Their Heart and Kidney Indications Compare?
Both brands now have cardiovascular indications for defined groups with type 2 diabetes. Mounjaro’s August 2026 label includes adults at high cardiovascular risk. Ozempic’s label specifies adults with established cardiovascular disease and also includes a kidney-related indication in adults with type 2 diabetes and chronic kidney disease.
SURPASS-CVOT, described in Mounjaro’s current label, compared tirzepatide with dulaglutide. It was not a cardiovascular comparison with Ozempic.
This result cannot establish Mounjaro’s superiority over semaglutide for preventing heart attacks or strokes.
SELECT is a different question: it studied semaglutide 2.4 mg in adults with established cardiovascular disease and overweight or obesity, without diabetes.
It underpins Wegovy’s cardiovascular evidence; it should not be described as an Ozempic trial in people with diabetes.
Are Mounjaro and Ozempic Approved for Weight Loss?
A clinician may consider off-label treatment when appropriate, but an off-label prescription does not guarantee insurance payment. The exact product, diagnosis and plan criteria matter.
- •Coverage is not automatic. For a weight-management indication, investigate the relevant Wegovy or Zepbound benefit with your plan. For type 2 diabetes, check the plan’s criteria for Mounjaro or Ozempic.
- •Dose schedules differ. Ozempic has a 2 mg maximum; the current Wegovy label includes additional formulations and doses. Do not treat a brand switch or the larger milligram number as a dose conversion.
If weight loss is your goal and you don't have diabetes, the cleaner path is the on-label twin: Zepbound vs Mounjaro for tirzepatide, or Wegovy vs Zepbound and Ozempic vs Wegovy for the semaglutide side.
That keeps you on-label and gives you the best shot at coverage.
What Do Mounjaro and Ozempic Cost?
Separate list price, an eligible insurance copay, a manufacturer cash offer and a telehealth service fee. Your total depends on the prescribed product and plan.
Our Ozempic savings guide and Mounjaro savings guide explain the branded routes before you compare other products.
If you're paying cash, telehealth companies advertise lower-priced compounded products, but they are not FDA-approved versions or generics of Mounjaro, Zepbound, Ozempic, or Wegovy:
- •Compounded tirzepatide: Gala lists it from $99/mo on its annual plan, billed once a year. Confirm the full annual charge before paying. FDA has not reviewed this compounded product as identical or equivalent to Mounjaro or Zepbound.
- •Compounded tirzepatide AND semaglutide under one program: TrimRx lists GLP-1 at $174 month-to-month or $149/mo on a 12-month plan, and GLP-1 + GIP at $279 month-to-month or $249/mo on 12 months. Confirm the full bill and renewal; generic package terms do not establish the next price-lock charge. Compounded only, no brand-name options; total under review.
- •Multiple compounded formats: SkinnyRx lists five compounded options, but FDA warning letter #717989 over its labeling and marketing is part of the record; the letter does not allege unsafe medication.
- •Lowest-cost featured pick: Embody, from $79/mo on a selected plan.
To see every program ranked and priced, start with our best GLP-1 providers and the cheapest GLP-1 options.
For the full pricing breakdown by drug, see the GLP-1 cost guide, tirzepatide cost, and the compounded tirzepatide guide.
Run your specific numbers on the cost calculator.
Compounded tirzepatide and semaglutide are made by licensed compounding pharmacies and are not FDA-approved finished products, they are not reviewed by the FDA for safety, effectiveness, or quality the way brand Mounjaro and Ozempic are.
The rules on compounding have been changing, and the FDA is the one changing them. Read the compounded guides above before deciding, and use a provider that works with a licensed US pharmacy.
How Do Their Side Effects Compare?
Both drugs share the GLP-1 side-effect profile, and the most common adverse events are gastrointestinal, nausea, diarrhea, vomiting, and constipation, concentrated during the dose-escalation phase.
Slow, gradual dose increases are the main way doctors limit them.
The SURMOUNT-5 abstract reports that gastrointestinal effects were common in both groups, generally mild to moderate and most frequent during dose escalation.
That was a weight-management trial without diabetes; it does not settle which diabetes medicine you personally would tolerate better.
Both carry a boxed warning for the risk of thyroid C-cell tumors based on rodent studies, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
For a practical playbook on managing day-to-day symptoms, see our GLP-1 side effects management guide.
Frequently Asked Questions
Tirzepatide produced greater average weight loss at the doses tested in SURMOUNT-5, but that trial studied weight-management injections in adults without diabetes.
It did not compare Ozempic 2 mg with Mounjaro 15 mg in people with diabetes. Neither brand is approved for weight management.
No. Mounjaro contains tirzepatide, which activates GIP and GLP-1 receptors. Ozempic contains semaglutide, which activates GLP-1 receptors. They are different prescriptions with distinct dose schedules and indications.
SURPASS-2 found greater HbA1c reductions with the studied tirzepatide doses than with semaglutide 1 mg.
That does not establish the exact comparison against Ozempic 2 mg or the best prescription for an individual patient.
Both have cardiovascular risk-reduction indications for specified adults with type 2 diabetes.
Read the current Mounjaro and Ozempic labels with your clinician.
SELECT studied Wegovy-dose semaglutide in a different population; it is not an Ozempic-versus-Mounjaro heart-outcome trial.
Neither brand is approved for weight management. Coverage for that use depends on the plan and is not assured. Ask about the exact diagnosis and the relevant approved product before paying for an appointment or prescription.
Our insurance lookup can direct you to plan-specific checks.
Compounded versions can have lower advertised entry points: Gala lists compounded tirzepatide from $99/mo on an annually billed plan, while Embody lists semaglutide from $79/mo on a selected plan.
TrimRx lists GLP-1 at $174 month-to-month or $149/mo on a 12-month plan, and GLP-1 + GIP at $279 month-to-month or $249/mo on 12 months.
The complete payment and renewal remain unconfirmed; generic package terms are a separate published schedule. Compare all cash paths on our /cheapest page. Compounded drugs are not FDA-approved finished products.
Mounjaro and Ozempic are injectable brands. Approved oral semaglutide products have separate labels; our oral GLP-1 guide explains them.
A compounded dissolving tirzepatide tablet is not an FDA-approved Mounjaro tablet, and it cannot inherit the injection trial results.
Both commonly cause gastrointestinal symptoms. A clinician should compare your symptoms, dose, other medicines and health history; separate trial percentages are not a reliable guide to your personal tolerability.
See our side-effect management guide.
A clinician can assess that change, but there is no simple milligram-for-milligram conversion. Give your prescriber your exact product, dose, last administration and side effects.
The Mounjaro and Ozempic labels have different schedules; do not combine or change them using an online comparison chart.
What Is the Next Useful Step?
Take the diabetes and weight-management evidence to your prescriber, then compare the product they consider appropriate.
For weight management, read Wegovy versus Zepbound; for the ingredient and formulation differences, read semaglutide versus tirzepatide.
If considering compounded cash-pay options, keep their approval status and product evidence separate from branded trial results.
Start with the best GLP-1 providers, find your lowest price on /cheapest, or take the 2-minute match quiz to see which program fits your situation.
This article is for informational purposes only and is not medical advice. It does not establish a doctor-patient relationship.
Mounjaro and Ozempic are prescription medications; tirzepatide and semaglutide carry a boxed warning for thyroid C-cell tumors and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.
Off-label use, compounded products, and any change to your medication should be discussed with a licensed healthcare provider who knows your full medical history.
GLP-1 Picks is an independent comparison site and may earn a commission when you choose a provider through our links; this never affects our editorial scoring, which is based on a fixed methodology.
Sources
- SURMOUNT-5 original trial, Aronne et al., NEJM, 2025
- SURPASS-2 original trial, Frías et al., NEJM, 2021
- Mounjaro prescribing information, Eli Lilly, revised August 2026
- Ozempic prescribing information, Novo Nordisk, revised May 2026
- Wegovy prescribing information, Novo Nordisk, revised June 2026
- Zepbound prescribing information, Eli Lilly, revised August 2026
Some links pay us a commission. That never changes a score or a ranking. How we work
Affiliate disclosure: Some links in this article are affiliate links. If you join a program through one, we may earn a commission at no extra cost to you.
Where to go next
What the doctors say
Quotes from named doctors and medical bodies, each linked to where they said it. We did not ask for them, and they do not endorse any provider.
“People with overweight or obesity have individual preferences, and with oral semaglutide as a potential new treatment option, more of those who are not on treatment today may consider starting GLP-1 treatment.”
“We now have medicines that not only reduce heart attacks, strokes, and peripheral arterial disease, but also simultaneously lead to meaningful weight loss, which in turn lowers the risk of many weight-related conditions. These treatments also improve patients' quality of life in a meaningful way, making this a genuine win, win.”
“It's the first time that we have seen this magnitude of weight loss compared to current medications on the market for obesity. It's 1.5 to 2.5 times more effective than currently available drugs.”
Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.
